Overlooking the obvious? On the potential of treatment alterations to predict patient-specific therapy response

被引:2
|
作者
Roeder, Ingo [1 ,2 ]
Glauche, Ingmar [1 ]
机构
[1] Tech Univ Dresden, Inst Med Informat & Biometry, Carl Gustav Carus Fac Med, Fetscherstr 74, D-01307 Dresden, Germany
[2] Natl Ctr Tumor Dis NCT, Core Unit Data Management & Analyt, Partner Site Dresden, Dresden, Germany
关键词
D O I
10.1016/j.exphem.2020.11.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Prognostic or therapeutic classification of diseases is often based on clinical or genetic characteristics at diagnosis or response landmarks determined at a certain time point of treatment. On the other hand, there are more and more means, such as molecular markers and sensor data, that allow for quantification of disease or therapeutic parameters over time. Although a general value of time-resolved disease monitoring is widely accepted, the full potential of using the available information on disease and treatment dynamics in the context of outcome prediction or individualized treatment optimization still seems to be, at least partially, overlooked. Within this Perspective, we summarize the conceptual idea of using dynamic information to obtain a better understanding of complex pathophysiological processes within their particular "host environment," which also allows us to intrinsically map patient-specific heterogeneity. Specifically, we discuss to which extent treatment alterations can provide additional information to understand a patient's individual condition and use this information to further adapt the therapeutic strategy. This conceptual discussion is illustrated by using examples from myeloid leukemias to which we recently applied this concept using statistical and mathematical modeling. (c) 2020 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:26 / 30
页数:5
相关论文
共 50 条
  • [1] Modeling Common and Patient-Specific RestingState Connectivity to Predict Craving and Smoking Cessation Treatment Response
    Murray, Laura
    Frederick, Blaise
    Janes, Amy
    DRUG AND ALCOHOL DEPENDENCE, 2024, 260
  • [2] Patient-specific antiplatelet therapy
    Conde, ID
    Kleiman, NS
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2004, 17 (01) : 63 - 77
  • [3] Patient-Specific Antiplatelet Therapy
    Ian D. Conde
    Neal S. Kleiman
    Journal of Thrombosis and Thrombolysis, 2004, 17 : 63 - 77
  • [4] PATIENT-SPECIFIC VIRTUAL CONTROLS CAN BE USED TO SIMULATE AND PREDICT RESPONSE TO RADIATION THERAPY IN INDIVIDUAL GLIOBLASTOMA PATIENTS
    Swanson, Kristin R.
    Rockne, Russ
    Rockhill, Jason K.
    Mrugala, Maciej
    Alvord, Ellsworth C., Jr.
    NEURO-ONCOLOGY, 2009, 11 (06) : 929 - 929
  • [5] PATIENT-SPECIFIC DOSIMETRY IN RADIONUCLIDE THERAPY
    Lyra, Maria
    Lagopati, Nefeli
    Charalambatou, Paraskevi
    Vamvakas, Ioannis
    RADIATION PROTECTION DOSIMETRY, 2011, 147 (1-2) : 258 - 263
  • [6] Patient-Specific Dosimetry for Photodynamic Therapy
    Finlay, Jarod C.
    Li, Jun
    Zhou, Xiaodong
    Zhu, Timothy C.
    PROCEEDINGS OF LIGHT-ACTIVATED TISSUE REGENERATION AND THERAPY CONFERENCE, 2008, 12 : 115 - +
  • [7] Fluorescence-Based Quantitative and Spatial Analysis of Tumour Spheroids: A Proposed Tool to Predict Patient-Specific Therapy Response
    Spoerri, Loredana
    Gunasingh, Gency
    Haass, Nikolas K.
    FRONTIERS IN DIGITAL HEALTH, 2021, 3
  • [8] Patient-specific intracranial pressure Response
    Lazaridis, Christos
    Czosnyka, Marek
    JOURNAL OF NEUROSURGERY, 2014, 120 (04) : 892 - 892
  • [9] Can We Predict Mutant Neoepitopes in Human Cancers for Patient-Specific Vaccine Therapy?
    Lutz, Eric R.
    Jaffee, Elizabeth M.
    CANCER IMMUNOLOGY RESEARCH, 2014, 2 (06) : 518 - 521
  • [10] Patient-specific HLA-I subtypes predict response to immune checkpoint blockade
    Shohdy, Kyrillus S.
    Atherton, Jack
    Longland, Jessica
    Alison, Jennifer
    Pillai, Manon
    Thistlethwaite, Fiona
    ONCOIMMUNOLOGY, 2025, 14 (01):